Dashboard
1
Negative results in Mar 25
- INTEREST(Q) At CNY 6.86 MM has Grown at 19.17%
- INTEREST COVERAGE RATIO(Q) Lowest at 1,378.97
- RAW MATERIAL COST(Y) Grown by 5.07% (YoY)
2
With ROE of 14.14%, it has a expensive valuation with a 4.92 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,735 Million (Large Cap)
35.00
NA
0.18%
-0.08
14.14%
4.92
Revenue and Profits:
Net Sales:
424 Million
(Quarterly Results - Jun 2025)
Net Profit:
117 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.42%
0%
-23.42%
6 Months
-14.99%
0%
-14.99%
1 Year
-34.12%
0%
-34.12%
2 Years
-43.77%
0%
-43.77%
3 Years
-50.3%
0%
-50.3%
4 Years
-49.23%
0%
-49.23%
5 Years
-35.57%
0%
-35.57%
Eyebright Medical Technology (Beijing) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
49.20%
EBIT Growth (5y)
49.05%
EBIT to Interest (avg)
83.12
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.40
Tax Ratio
9.26%
Dividend Payout Ratio
17.06%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.21%
ROE (avg)
12.24%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
4.92
EV to EBIT
31.69
EV to EBITDA
23.01
EV to Capital Employed
5.29
EV to Sales
9.04
PEG Ratio
1.72
Dividend Yield
0.18%
ROCE (Latest)
16.68%
ROE (Latest)
14.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
424.50
352.40
20.46%
Operating Profit (PBDIT) excl Other Income
178.80
136.20
31.28%
Interest
4.90
6.90
-28.99%
Exceptional Items
-0.40
0.50
-180.00%
Consolidate Net Profit
117.10
89.80
30.40%
Operating Profit Margin (Excl OI)
323.40%
268.60%
5.48%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 20.46% vs 6.34% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 30.40% vs 8.19% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,395.90
936.20
49.10%
Operating Profit (PBDIT) excl Other Income
573.60
394.60
45.36%
Interest
21.00
10.00
110.00%
Exceptional Items
-4.20
-1.80
-133.33%
Consolidate Net Profit
387.10
286.10
35.30%
Operating Profit Margin (Excl OI)
306.70%
329.10%
-2.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 49.10% vs 64.02% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 35.30% vs 25.92% in Dec 2023
About Eyebright Medical Technology (Beijing) Co., Ltd. 
Eyebright Medical Technology (Beijing) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






